SCHEMBL3017340

SCHEMBL3017340

O=S(=O)(c1cccc(Cl)c1Cl)N1CCN(c2nc(-c3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.60
MAPT P10636 6/20 0.60
LMNA P02545 5/20 0.60
KMT2A Q03164 4/20 0.60
ALDH1A1 P00352 3/20 0.60
MEN1 O00255 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.54
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MAPK1 P28482 5/20 0.50
RAB9A P51151 3/20 0.46
AR P10275 1/20 0.44
TSHR P16473 1/20 0.44
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017183 0.94 KMT2A (0.60) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3012556 0.94 SMN1; SMN2 (0.60) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3007292 0.92 SMN1; SMN2 (0.62) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3014513 0.89 MAPT (0.57) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3011306 0.89 MAPT (0.62) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3014926 0.88 SMN1; SMN2 (0.62) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3010147 0.88 SMN1; SMN2 (0.56) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3016918 0.87 SMN1; SMN2 (0.59) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3020238 0.86 MAPT (0.55) SMN1; SMN2MAPTLMNAKMT2AALDH1A1
SCHEMBL3009026 0.86 SMN1; SMN2 (0.56) SMN1; SMN2MAPTLMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885MAPT 18/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.